NAME OF DRUG : SELONSERTIB
ALSO KNOWN AS : GS-4997
LABORATORY : GILEAD
STATUS AND ADVANCEMENT
Type of drug : (ASK1) inhibitor
Clinical trials advancement : Recruiting Phase 3
The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3
Estimated time to market : 29 months.
LABORATORY ABSTRACT ON THE DRUG
Selonsertib is an investigational small molecule inhibitor of ASK1, a protein that promotes inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH.
RECENT NEWS ON SELONSERTIB
2016-11-14 : Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016
SOME PUBLICATIONS RELATED WITH SELONSERTIB
March 2018 : The ASK1 Inhibitor Selonsertib in Patients With Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial
December 2017 : The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
September 2017 : The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial
July 2017 : Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease
April 2017 : Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects
June 2016 : Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer
October 2012 : Therapeutic targets in the ASK1-dependent stress signaling pathways
April 2010 : Abstract 1201: Inhibition of ASK1 through phosphorylation of serine 967 by PI3K/Akt-mediated pathways